Indeed, many of these patients should receive GLP-1 receptor agonists (GLP1-RA) and SGLT2 inhibitors (SGLT2i) [3] after landmarking trials with both drug classes have proved considerable benefits in terms of reduction of HF incidence and hospitalization, major cardiovascular (CV) and renal events and CV mortality [4–7]. This evidence concerns the gene GLP1R and hydrops fetalis.